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A 68-year-old woman was admitted to the regional hospital because of hemolytic anemia,
thrombocytopenia, and neurological abnormalities including unconsciousness. One week
before admission, she suffered from diarrhea and subsequently passed out and hit her face
on the ground. She was suspected of having TTP and was transferred to our hospital. We
performed the assays of ADAMTS13 activity and anti-ADAMTS13 antibody titers, and con-
ﬁrmed the diagnosis of acquired idiopathic TTP with total deﬁciency of ADAMTS13 activity
with its inhibitor. She was initially treated with plasma exchange combined with cortico-
steroids, however, we were forced to substitute plasma exchange with fresh frozen plasma
infusion due to procedure-associated complications. The infusion of fresh frozen plasma
was known as less effective and more likely to boost inhibitor titers compared to plasma
exchange. In this circumstance, we could successfully switch the plasma therapy under
close monitoring of ADAMTS13 activity and anti-ADAMTS13 antibody titers which pre-
cisely revealed the disease status of TTP in our patient, and eventually she achieved com-
plete remission with normal level of ADAMTS13 activity and no inhibitor. Our experience
suggested that the measurement of ADAMTS13 activity and inhibitor titer might be valu-
able not only for making the diagnosis but also for guiding treatment decisions by precise
evaluating of disease status in patients with the acquired form of TTP.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction integrin-like and metalloproteinase with thrombospondinThrombotic thrombocytopenic purpura (TTP) is a life-
threatening systemic disorder characterized by the clinical
pentad of microangiopathic hemolytic anemia, thrombocy-
topenia, renal failure, ﬂuctuating neurological signs, and
fever [1,2]. Severe deﬁciency of plasma ADAMTS13 (a dis-type 1 motifs 13) activity has been identiﬁed in patients
with TTP, but not in patients with hemolytic uremic syn-
drome (HUS) [3,4]. ADAMTS13 is a metalloprotease that
speciﬁcally cleaves the Tyr1605–Met1606 bond in the A2
domain of von Willebrand factor (VWF) [5–9]. In the ab-
sence of ADAMTS13 activity, unusually large VWF multi-
mers (UL-VWFMs) are released from vascular endothelial
cells, which accumulate in the circulation and induce the
formation of platelet thrombi in the microvasculature un-
der conditions of high shear stress, resulting in thrombocy-
topenia and multi-organ dysfunction [10]. TTP consists of 2
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ital TTP, Upshaw–Schulman syndrome (USS), ADAMTS13
deﬁciency is due to mutations in ADAMTS13 [11–14]. Ac-
quired TTP is caused by inhibitory autoantibodies against
ADAMTS13 [15,16]. Plasma exchange (PE) combined with
steroid therapy has been established as ﬁrst-line therapy
for acquired TTP [17]. Combination therapy should be ini-
tiated as soon as possible when TTP is suspected; however,
it was often delayed due to difﬁculties in differentiating
TTP from HUS unless ADAMTS13 activity is measured. Con-
venient and highly sensitive assays of ADAMTS13 activity
and titers of its inhibitor have been developed [18,19],
and they have been conﬁrmed to be quite useful for mak-
ing the diagnosis of TTP. However, the usefulness of mon-
itoring these values to evaluate treatment response
remained unclear.
Herein we describe an elderly patient with acquired TTP
who was successfully treated with PE and corticosteroids
followed by plasma infusion while ADAMTS13 activity
and inhibitor titers were being monitored. Our experience
suggests that close monitoring of these ADAMTS13 param-
eters might be helpful for the precise evaluation of treat-
ment response in patients with TTP.2. Case report
A 68-year-old woman was admitted to the regional hos-
pital because of hemolytic anemia, thrombocytopenia, and
neurological abnormalities including unconsciousness.
One week before admission, she suffered from diarrhea
and subsequently passed out and hit her face on the
ground. She was suspected of having TTP and was trans-
ferred to our hospital. On admission, she had a disorder
of consciousness, purpura on her face and extremities,
and icterus. Laboratory ﬁndings included an increased
white blood cell count (13.3  109/L) with immature gran-
ulocytes and erythroblasts, decreased red blood cell count
(1.49  1012/L), increased reticulocyte count (0.16  1012/
L), and severely decreased platelet count (6  109/L). Schis-
tocytes (5%) were detected on the blood ﬁlm. The levels of
aspartate aminotransferase (114 IU/L), alanine amino-
transferase (40 IU/L), lactate dehydrogenase (1714 IU/L),
total bilirubin (5.2 mg/dL), uric acid (8.7 mg/dL), blood
urea nitrogen (58.7 mg/dL), and creatinine (1.3 mg/dL)
were elevated. Haptoglobin was under the detection limit.
Hemostatic tests showed increased levels of ﬁbrin degra-
dation products (FDP, 17.6 lg/mL), D-dimer (8.7 lg/mL),
TAT (24.4 lg/L), PIC (1.5 lg/mL), and thrombomodulin
(TM, 4.1 FU/mL). Levels of ﬁbrinogen (217.7 mg/dL) and
anti-thrombin III (103.9%) were normal. Stool samples
were negative for enteropathogenic Escherichia coli, Shiga
toxin, and O-157 LPS. Bone marrow examination revealed
no abnormalities. We suspected acquired idiopathic TTP
because she fulﬁlled the clinical pentad, and immediately
initiated PE combined with steroid pulse therapy. On the
second hospital day (HD), assays of ADAMTS13 activity
and ADAMTS13 inhibitor titers were performed. Plasma
levels of ADAMTS13 activity and ADAMTS13 inhibitor ti-
ters were measured by a chromogenic ADAMTS13-act-ELI-
SA (Kainos Inc., Tokyo, Japan) [19]. The ADAMTS13 activityof pooled plasma samples from normal controls was de-
ﬁned as 100%, and the detection limit of this assay was
0.5% of the normal controls. The ADAMTS13 inhibitor titers
were expressed in Bethesda units (BU), where 1 BUwas de-
ﬁned as the amount necessary to reduce ADAMTS13 activ-
ity to 50% of control. A titer of <0.5 BU/mL was considered
to be negative. We conﬁrmed the diagnosis of acquired idi-
opathic TTP with values of ADAMTS13 activity and inhibi-
tor titers, which were less than 0.5% and 1.4 BU/mL,
respectively (see Fig. 1).
Although the patient was treated with a standard regi-
men of PE combined with steroid therapy for idiopathic
TTP, she developed severe convulsions followed by apnea,
necessitating mechanical ventilation. Computed tomogra-
phy of the head did not show any intracranial complica-
tions such as hemorrhage or infarction, and we continued
PE for 5 consecutive days. On HD 2, ADAMTS13 activity le-
vel rose to 8.8% and ADAMTS13 inhibitor titers dropped to
0.9 BU/mL. These results suggested she responded well to
PE plus steroid therapy. Subsequently, her platelet count
gradually increased without any transfusions of platelets,
reaching 50  109/L on HD 5. On HD 7, the platelet count
was increased (98  109/L), plasma levels of lactate dehy-
drogenase were decreased (396 IU/L), and the red blood
cell count was increased (2.50  1012/L). We were con-
vinced that her clinical condition was remarkably im-
proved because the values of ADAMTS13 activity and
ADAMTS13 inhibitor titers were 5.8% and <0.1 BU/mL,
respectively. Although these results strongly suggested
that her clinical condition was improving, we were forced
to substitute PE with fresh frozen plasma (FFP) transfusion
(400 mL/day) because her circulatory system was unstable
during PE. We also carefully tapered the steroid dose.
Mechanical ventilation discontinued on HD 8. Subse-
quently, schistocytes were not detected on HD 10, and
the platelet count normalized by HD 14. ADAMTS13 activ-
ity increased to 25% on HD 15, 50% on HD 23, and 75% on
HD 41. Based on these results, we decreased the frequency
of FFP infusion to 3 times a week on HD 26, and discontin-
ued it on HD 51. She was discharged from our hospital on
HD 62.3. Discussion
Herein we presented the case of an elderly female pa-
tient with acquired idiopathic TTP initially treated with
PE and corticosteroids that was subsequently changed to
FFP infusion due to procedure-associated complications.
PE was established as ﬁrst-line therapy by randomized
clinical trials for acquired TTP [20]. The treatment objec-
tives of PE are not only to remove anti-ADAMTS13 neutral-
izing autoantibodies, UL-VWFM, and harmful cytokines
from the circulation of TTP patients, but also to replenish
ADAMTS13. In fact, urgent introduction of PE reduced mor-
tality to 10% or less. In this context, it was acceptable to
initiate PE even when not all of the diagnostic criteria were
fulﬁlled. Corticosteroids are used in conjuction with PE to
reduce the production of speciﬁc inhibitors against ADAM-
TS13. PE is sometimes associated with complications re-
lated to venous access, including bleeding and infection.
0 
5 
10
15
20
25
30
0 
500
1000
1500
2000
LD
H
(U
/L
)
PL
T 
(1
01
0 /
L)
H
b㧔
g/
dl
㧕
0 
0.5
1 
1.5
2 
2.5
0 
20
40
60
80
100
A
D
A
M
TS
13
:A
C 
(%
) 
A
D
A
M
TS
13
:IN
H
 (B
U
/m
l)
mPSL  
(mg/day)
1000
500
125 60 50 40 30
PEX (40 U/day) FFP infusion (5 U/times)
7 times/week
3 times/week twice/week
10 20 30 40 500 
Fig. 1. Change of laboratory data and clinical course in the patient with acquired thrombotic thrombocytopenia purpura. She was diagnosed as having
acquired idiopathic TTP because her ADAMTS13:AC and ADAMTS13:INH) were less than 0.5% and 1.4 BU/mL, respectively. She was introduced to standard
therapy for idiopathic TTP, including plasma exchange and steroid pulse. We continued PE during ﬁve consecutive days, and her platelet count reached up
to 50  109/L on the 5th HD. On 7th HD, she showed increased platelet count (98  109/L), decreased plasma level of lactate dehydrogenase (396 IU/L), and
the values of ADAMTS13:AC and ADAMTS13:INH was 5.8% and <0.1 BU/mL, respectively. Because of the complication associated PE procedures, we changed
PE for the infusion of fresh frozen plasma (FFP) (400 mL/day) every day, and carefully tapered the dosage of steroid. Fortunately, she recovered from apnea
on the 8th HD, schistocytes were not detected on 10th HD, and platelet count normalized on 14th HD. The values of ADAMTS13:AC increased up to 25% on
15th day, 50% on 23rd HD, and 75% on 41st HD, respectively. Based on these results, we changed FFP infusion 3 times a week on 26th HD, and successfully
stopped on 51st HD. Finally, she discharged our hospital on 62nd HD.
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sion and transfusion reactions [21,22]. PE might not be tol-
erated by elderly frail adults or young patients with TTP
because it is associated with systemic circulatory insufﬁ-
ciency, which can result in stroke, cardiac complications,
and renal failure.
In fact, our patient developed cardiac insufﬁciency due
to PE. Thus, we modiﬁed her treatment, changing PE to
FFP infusion, and carefully observed her disease status un-
der close monitoring of levels of ADAMTS13 activity and ti-
ters of its inhibitor. It is known that some patients with
acquired idiopathic TTP do not respond to PE. Such patients
usually have relatively high titers of ADAMTS13 inhibitor
which remain present throughout treatment. Furthermore,
some patients have a boost in anti-ADAMTS13 inhibitor
levels after initiation of PE. Recently, Isonishi et al. reported
6 Japanese patients with acquired TTP with increased titers
of anti-ADAMTS13 inhibitor after PE treatment as demon-
strated by monitoring. They demonstrated that rituximab,
a chimeric monoclonal antibody directed against the CD20
antigen on B lymphocytes, was highly effective for the
treatment of those patients [23]. These results suggest that
measurement of both ADAMTS13 activity and levels of its
inhibitor might be important not only for diagnosing TTP
but also for guiding treatment.
Currently PE combined with corticosteroids would be
implemented as ﬁrst-line therapy in all patients with ac-
quired idiopathic TTP and continued until resolution of
their clinical symptoms and normalization of their labora-
tory data. In clinical practice, platelet count and lactatedehydrogenase level are usually used to assess disease sta-
tus and treatment efﬁcacy. Recently, Yang et al. reported
the clinical usefulness of measuring ADAMTS13 antigen
levels during the course of treatment [24]. They found that
ADAMTS13 antigen levels are more variable when ADAM-
TS13 activity is severely deﬁcient. They also showed that
severe deﬁciency of ADAMTS13 antigen at disease onset
and poor recovery of this value during therapy are associ-
ated with poor prognosis. Thus, they concluded that mea-
suring ADAMTS antigen levels provides useful
information for the management of patients with acquired
TTP. However, the measurement of ADAMTS13 antigen
levels is not yet commercially available, making monitor-
ing inconvenient. In this context, monitoring of ADAMTS13
activity and inhibitor titers would provide useful data for
the management of patients with acquired idiopathic TTP.
In conclusion, we successfully treated an elderly frail
patient with acquired idiopathic TTP under close monitor-
ing of ADAMTS13 activity and inhibitor titers. The mea-
surement of these parameters might be valuable not only
for the diagnosis of TTP but also for guiding treatment
decisions.Acknowledgement
The authors thank Ms. Ayami Isonishi in Department of
Blood Transfusion Medicine, Nara Medical University for
her excellent technical assistance performing ADAMTS13
activity and inhibitor assays.
238 K. Sano et al. / Transfusion and Apheresis Science 50 (2014) 235–238References
[1] Moschcowitz E. Hyaline thrombosis of the terminal arterioles and
capillaries: a hitherto undescribed disease. Proc NY Pathol Soc
1924;24:21–4.
[2] Amorosi EL, Ultman JE. Thrombotic thrombocytopenic purpura:
report of the 16 cases and review of the literature. Medicine
1966;45:139–59.
[3] Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B,
et al. Von Willebrand factor-cleaving protease in thrombotic
thrombocytopenic purpura and the hemolytic-uremic syndrome. N
Engl J Med 1998;339:1578–84.
[4] Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving
protease in acute thrombotic thrombocytopenic purpura. N Engl J
Med 1998;339:1585–94.
[5] Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T,
Nakagaki T, et al. A novel human metalloprotease synthesized in
the liver and secreted into the blood: possibly, the von Willebrand
factor-cleaving protease? J Biochem 2001;130:475–80.
[6] Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM,
et al. Mutations in a member of the ADAMTS gene family cause
thrombotic thrombocytopenic purpura. Nature 2001;413:488–94.
[7] Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K.
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a
metalloprotease involved in thrombotic thrombocytopenic purpura.
J Biol Chem 2001;276:41059–63.
[8] Fujikawa K, Suzuki H, McMullen B, Chung D. Puriﬁcation of human
von Willebrand factor-cleaving protease and its identiﬁcation as a
new member of the metalloproteinase family. Blood
2001;98:1662–6.
[9] Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid
sequence of puriﬁed von Willebrand factor-cleaving protease. Blood
2001;98:1654–61.
[10] Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K.
Von Willebrand factor-cleaving protease and Upshaw–Schulman
syndrome. Int J Hematol 2002;75:25–34.
[11] Upshaw Jr JD, Reidy TJ, Groshart K. Thrombotic thrombocytopenic
purpura in pregnancy: response to plasma manipulations. South
Med J 1985;78:677–80.
[12] Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on
thrombopoiesis. I. A factor in normal human plasma required for
platelet production; chronic thrombocytopenia due to its deﬁciency.
Blood 1960;16:943–57.
[13] Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, Funato M,
et al. Upshaw–Schulman syndrome revisited: a concept of
congenital thrombotic thrombocytopenic purpura. Int J Hematol
2001;74:101–8.[14] Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K,
et al. Natural history of Upshaw–Schulman syndrome based on
ADAMTS13 gene analysis in Japan. J Thromb Haemostasis: JTH
2011;9(Suppl. 1):283–301.
[15] Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deﬁciency of
von Willebrand factor-cleaving protease in a patient with
thrombotic thrombocytopenic purpura. Blood 1998;91:2839–46.
[16] Matsumoto M, Bennett CL, Isonishi A, Qureshi Z, Hori Y, Hayakawa
M, et al. Acquired idiopathic ADAMTS13 activity deﬁcient
thrombotic thrombocytopenic purpura in a population from Japan.
PLoS One 2012;7:e33029.
[17] Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis
and management of the thrombotic microangiopathic haemolytic
anaemias. Br J Haematol 2003;120:556–73.
[18] Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region
from D1596 to R1668 of von Willebrand factor, provides a minimal
substrate for ADAMTS-13. Blood 2004;103:607–12.
[19] Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y.
Novel monoclonal antibody-based enzyme immunoassay for
determining plasma levels of ADAMTS13 activity. Transfusion
2006;46:1444–52.
[20] Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC,
et al. Comparison of plasma exchange with plasma infusion in the
treatment of thrombotic thrombocytopenic purpura. Canadian
Apheresis Study Group. N Engl J Med 1991;325:393–7.
[21] Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, et al.
Complications of plasma exchange in 71 consecutive patients
treated for clinically suspected thrombotic thrombocytopenic
purpura–hemolytic–uremic syndrome. Transfusion
2000;40:896–901.
[22] McMinn Jr JR, Thomas IA, Terrell DR, Duvall D, Vesely SK, George JN.
Complications of plasma exchange in thrombotic thrombocytopenic
purpura–hemolytic uremic syndrome: a study of 78 additional
patients. Transfusion 2003;43:415–6.
[23] Isonishi A, Plaimauer B, Scheiﬂinger F, Nishio K, Uchiba M, Yonemura
Y, et al. Anti-ADAMTS13 inhibitor boosting with plasma exchange in
acquired TTP: characterization of inhibitors and efﬁcient treatment
with rituximab. In: XXIII congress of ISTH 2011 (Kyoto) Abstract P-
WE-475; 2011. <http://wwwisth2011com/prgrm-common/
abstracts/html/00742html.
[24] Yang S, Jin M, Lin S, Cataland S, Wu H. ADAMTS13 activity and
antigen during therapy and follow-up of patients with idiopathic
thrombotic thrombocytopenic purpura: correlation with clinical
outcome. Haematologica 2011;96:1521–7.
